Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Clarke

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Eclinicalmedicine|July 21, 2021
The epidemiology of kidney disease in people of African ancestry with HIV in the UKRachel K Y Hung, Beatriz Santana-Suarez, Elizabeth Binns-Roemer, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Kidney International Reports|December 19, 2024
Corrigendum to "Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIV" [<i>Kidney International Reports</i> Volume 7, Issue 4, April 2022, Pages 786-796]Rachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
Kidney International Reports|May 2, 2022
Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Kidney International Reports|March 8, 2022
Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Eclinicalmedicine|July 21, 2021
The epidemiology of kidney disease in people of African ancestry with HIV in the UKRachel K Y Hung, Beatriz Santana-Suarez, Elizabeth Binns-Roemer, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Kidney International Reports|December 19, 2024
Corrigendum to "Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIV" [<i>Kidney International Reports</i> Volume 7, Issue 4, April 2022, Pages 786-796]Rachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
Kidney International Reports|May 2, 2022
Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Kidney International Reports|March 8, 2022
Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Pageof 13